Related Experiment Video
Updated: May 1, 2026
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
Prostate cancer: preventing metastasis to bone: is this the end of the story?
1Centre Hospitalier de I'Université de Montréal, Urology Division, Hôpital Notre-Dame, 1560 Sherbrooke Rast, Montreal, QC H2L 4M1, Canada.
Abstract:
A new report of zoledronic acid in men with high-risk prostate cancer is the latest in a long line of negative studies that have addressed the prevention of metastasis. We must learn from these studies so that potentially useful agents are not discarded due to poor trial design in the future.
Insights
Zoledronic acid did not prevent metastasis in men with high-risk prostate cancer. Future research should focus on improving clinical trial design to avoid discarding potentially effective agents.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastasis is a significant challenge in high-risk prostate cancer.
- Zoledronic acid is a bisphosphonate investigated for cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of zoledronic acid in preventing metastasis in men with high-risk prostate cancer.
Main Methods:
- A clinical trial involving men with high-risk prostate cancer was conducted.
- The study assessed the impact of zoledronic acid on metastasis prevention.
Main Results:
- The study reported negative findings regarding zoledronic acid's ability to prevent metastasis.
- This adds to a series of previous studies with similar outcomes.
Conclusions:
- Zoledronic acid is not effective in preventing metastasis in this patient population.
- Improving clinical trial design is crucial for future drug development and evaluation.
